Live Breaking News & Updates on குழு பகிர்

Stay updated with breaking news from குழு பகிர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Virbac: 2020 current operating income showed strong growth (+37.6% at constant rates and scope), reflecting the excellent evolution of revenue (+5.7% at constant rates and scope) and a sharp decrease in expenses


Virbac: 2020 current operating income showed strong growth (+37.6% at constant rates and scope), reflecting the excellent evolution of revenue (+5.7% at constant rates and scope) and a sharp decrease in expenses
+3.2%
1
2
13.8%
8.4
+21.6%
1
137.5
5
+9.5%
1 The change at constant exchange rates and scope is the organic growth, excluding the impact of exchange rate changes, by calculating the indicator for the financial year in question and the indicator for the previous financial year on the basis of identical exchange rates (the exchange rate used is the exchange rate in effect for the previous financial year), and excluding the impact of changes in scope (i.e. excluding Sentinel over both periods). ....

United States , France General , European Commission , Group Share , Financial Affairs Department , Sentinel Spectrum , Affairs Department , ஒன்றுபட்டது மாநிலங்களில் , பிரான்ஸ் ஜநரல் , ஐரோப்பிய தரகு , குழு பகிர் , நிதி வாழ்க்கைத்தொழில்கள் துறை , செண்டினல் ஸ்பெக்ட்ரம் , வாழ்க்கைத்தொழில்கள் துறை ,

Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results


Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results
March 04, 2021 16:42 ET
| Source:
Cellectis Inc.
Cellectis Inc.
New York, New York, UNITED STATES
Enrollment ongoing in 3 Cellectis-sponsored Phase 1 dose-escalation trials BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 7 leading US clinical centers
Preliminary results from our Phase 1 BALLI-01 clinical study of UCART22 in adults with r/r B-ALL presented in oral session at 2020 ASH Annual Meeting
Partner Allogene Therapeutics presented initial results from Phase 1 ALPHA clinical study of licensed ALLO-501 in r/r NHL at 2020 ASCO Annual Meeting and from Phase 1 UNIVERSAL clinical study of licensed ALLO-715 in r/r MM at 2020 ASH Annual Meeting ....

United States , New York , France General , North Carolina , Stanford University , Stephan Grupp , Laurent Poirot , Philippe Duchateau , Cytovia Theraputics , Kyung Nam Wortman , Steve Doares , Iovance Biotherapeutics , Simon Harnest , Mark Frattini , Leopold Bertea , Iovance Biotherapeutic , Carrie Brownstein , Jean Pierre Garnier , Margaret Gandolfo , Conor Mcgoldrick , Head Of Information Technology , Calyxt Inc , American Society Of Clinical Oncology , Clinical Development Appointments , Louis Pasteur University Of Strasbourg , Delta Consulting Group ,